2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Metabolic Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1379 Integration of genome-wide association studies and single-cell transcriptomics to define mutation-specific gene programs in clonal hematopoiesis

Camille Mei Chu, Thomas Koehnke, MD2, Asiri Ediriwickrema, MD, PhD3, Ravi Majeti, MD, PhD4
1 Stanford University School of Medicine, Palo Alto, California, United States
2 Stanford University School of Medicine, Palo Alto, California, United States
3 Stanford University School of Medicine, Palo Alto, California, United States
4 Stanford University School of Medicine, Palo Alto, California, United States

Introduction: Clonal hematopoiesis (CH) is characterized by the expansion of hematopoietic stem cells (HSCs) carrying somatic mutations in genes such as DNMT3A and TET2. CH confers increased risk for hematologic malignancies, including acute myeloid leukemia. Recent genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) associated with CH risk. However, the functional consequences of these genetic variants remain poorly understood. Most CH-associated variants are non-coding, and their associated functional target genes are largely unknown. Understanding how GWAS SNPs functionally impact hematopoiesis in a cell type and mutation-specific manner would provide insight into the underlying biology of CH and help nominate potential therapeutic strategies.

Methods: We systematically annotated CH-associated SNPs to prioritize candidate target genes and evaluated associated transcriptional programs in single-cell RNA sequencing (scRNA-seq) data. First, we performed a meta-analysis of CH GWAS data, aggregating results from three published studies (Kar et al. 2022, Wen et al. 2025, Dawoud et al. 2020). After standardizing effect sizes and filtering SNPs with P < 5*10-8 (Jannot et al. 2015), a standard threshold for GWAS analyses, we identified genome-wide significant associations. SNPs were classified by mutation specificity and ranked by statistical significance and effect size.

We then defined ±250kb genomic windows around each SNP and annotated all overlapping genes to capture potential regulatory targets. High-confidence candidate genes were prioritized based on the number of associated SNPs, replication across studies, and statistical strength. To generate robust gene expression signatures for GWAS-prioritized genes, we used convergent evidence from pathway annotations in the GeneCards database, experimentally validated protein-protein interactions from the STRING database, and literature searches. 

In parallel with the GWAS analysis, we analyzed four independent scRNA-seq datasets (121,710 total cells, 44 donors) of human bone marrow samples from CH patients and healthy controls (Jakobsen et al. 2024, Nam et al. 2023, Ediriwickrema et al. 2024, Li et al. 2021). Following standardized pre-processing and normalization, we conducted cell type annotation using a mixed model classifier (Ediriwickrema et al. 2025). Then, we quantified gene signature activity at the single-cell level using module scoring and compared signature activity between mutant and wild-type populations to assess dysregulation of GWAS genes in clonal populations.

Results: Our meta-analysis of CH GWAS data yielded high-confidence candidate genes spanning multiple mutation and functional contexts. From these prioritized genes, we constructed pathway-based gene expression signatures that encompassed well-characterized pathways and emerging biological processes with potential relevance to clonal expansion. Notably, several pathways appeared recurrently across multiple GWAS loci, including hematopoietic transcription factors, telomere maintenance and DNA replication, DNA damage response and repair, epigenetic regulation and chromatin modification, and cell signaling and calcium regulation.

Focusing on DNMT3A-mutant HSCs, we then compared gene signature activity between mutant and wild-type HSCs, and identified signatures significantly dysregulated in mutant HSCs, supported by statistics such as effect size (Cohen’s d) and multiple-testing corrected significance (q-value). These included putative regulatory targets within the ±250kb genomic windows of CH-associated SNPs involved in TNF receptor signaling and nucleotide metabolism. Of note, pathway dysregulation was restricted to HSCs for some target genes, but spanned across the early hematopoietic hierarchy for others, highlighting distinct gene and cell type patterns of dysregulation.

Conclusions: Our integrative approach links CH-associated genetic variants to functional transcriptomic dysregulation in mutant HSCs. By systematically prioritizing GWAS candidate genes and evaluating pathway signatures across four independent scRNA-seq datasets, we identified several candidate pathways with distinct patterns of dysregulation across the hematopoietic hierarchy. These findings demonstrate the utility of integrating GWAS and single-cell transcriptomic data to prioritize biological pathways underlying CH biology and provide mechanistic insights into clonal expansion.

Camille Mei Chu: No relevant conflicts of interest to declare.